The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Leqvio (inclisiran) and Repatha (evelocumab) are prescription injectable medications used to treat high cholesterol. They specifically target low-density lipoprotein cholesterol (LDL-C), or "bad ...

Leqvio lowers cholesterol by preventing your liver from making PCSK9. If you use Repatha or Praluent, but it’s not lowering your cholesterol enough, your doctor may have you stop your current ...

Novartis NVS announced positive data on the cholesterol drug Leqvio (inclisiran) from the late-stage V-MONO study. Leqvio is the first and only small interfering RNA (siRNA) therapy to lower low ...

Leqvio, in combination with maximally tolerated statin therapy, is administered as an initial single subcutaneous injection, a second dose at 3 months, and continued treatment once every 6 months.

Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A healthcare professional administers it as an injection under the skin. Original Medicare Part B covers ...

Leqvio is a liquid that is injected under the skin by a health care professional in a health care setting. Each injection can be given into the thigh, stomach, or outer area of the upper arm.

Novartis is pinning high hopes on Leqvio, which gained FDA approval in late 2021. The campaign kicked off during the Oscars (before the big you-know-what) with Gloria’s spot.

Novartis said at launch Leqvio was likely to be a slow-growing brand, but it is now showing clear signs of gathered momentum, with sales in the first half of this year rocketing 137% to $333 million.